Long-term outcomes of oligometastatic breast cancer patients treated with curative intent: an updated report

Nagasaki, Eijiro; Kudo, Rei; Tamura, Miho; Hayashi, Kazumi; Uwagawa, Tadashi; Kijima, Yoshikazu; Nogi, Hiroko; Takeyama, Hiroshi; Suzuki, Masafumi; Nishikawa, Masako; Yano, Shingo; Kobayashi, Tadashi

doi:10.1007/s12282-021-01240-1

Cited by 11 publications

(6 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this context, the number of metastatic sites was significantly associated with the likelihood of achieving a NED status, and the most solid odd-ratio for NED at the logistic regression analysis has been observed when setting 3 metastatic sites as cutoff [9]. A similar association has been observed in a smaller retrospective series of 73 unselected OM-BC patients (≤5 metastatic sites, ≤2 organs involved, ≤5 cm lesion dimeter), where ≤ 3 lesions were significantly associated with the probability of achieving a complete response after first-line chemotherapy [10,11]. Taken together, these data suggest that the cutoff of 3 metastatic lesions may better recapitulate the OM definition for BC patients.…”

Section: Clinical Landscape Of Om-bcsupporting

confidence: 67%

Oligometastatic breast cancer: Dissecting the clinical and biological uniqueness of this emerging entity. Can we pursue curability?

Visani¹,

Marini²,

Griguolo³

et al. 2022

Cancer Treatment Reviews

View full text Add to dashboard Cite

Section: Clinical Landscape Of Om-bcsupporting

confidence: 67%

Oligometastatic breast cancer: Dissecting the clinical and biological uniqueness of this emerging entity. Can we pursue curability?

Visani¹,

Marini²,

Griguolo³

et al. 2022

Cancer Treatment Reviews

View full text Add to dashboard Cite

“…Lan et al cite 48% of patients with triple negative or HER2 + OMBC [18]. These results are somewhat counterintuitive, since OMBC is traditionally described as an indolent disease [11,27,43,44]. The argument that its indolent nature could explain the observed prolonged survival must therefore be rethought.…”

Section: Discussionmentioning

confidence: 99%

Clinical and pathological characterization of 158 consecutive and unselected oligometastatic breast cancers in a single institution

Lacaze

Chira

Glemarec

et al. 2023

Breast Cancer Res Treat

View full text Add to dashboard Cite

Purpose: Data about incidence, biological and clinical characteristics of oligometastatic breast cancer (OMBC) are scarce. However, these data are essential in determining optimal treatment strategy. Gaining knowledge of these elements means observing and describing large, recent, and consecutive series of OMBC in their natural history.Methods: We collected data retrospectively at our institution from 998 consecutive patients diagnosed and treated with synchronous or metachronous metastatic breast cancer (MBC) between January 2014 and December 2018. The only criterion used to de ne OMBC was the presence of one to ve metastases at diagnosis.Results: Of 998 MBC, 15.8% were classi ed OMBC. Among these, 88% had one to three metastases, and 86.7% had only one organ involved. Bone metastases were present in 52.5% of cases, 20.9% had progression to lymph nodes, 14.6% to the liver, 13.3% to the brain, 8.2% to the lungs, and 3.8% had other metastases. 55.7% had HR+/HER2-OMBC, 25.3% had HER2+ OMBC, and 19% HR-/HER2-OMBC. The HR+/HER2-subtype statistically correlated with bone metastases (p=0.001), the HER2+ subtype with brain lesions (p=0.001), and the HR-/HER2-subtype with lymph node metastases (p=0.008). Visceral metastases were not statistically associated with any OMBC subtypes (p=0.186). OMBC-SBR grade III was proportionally higher than in the ESME series of 22,109 MBC (49.4% vs. 35.2%, p< 0.001).Conclusion: OMBC is a heterogeneous entity whose incidence is higher than has commonly been published. Not an indolent disease, each subgroup, with its biological and anatomical characteristics, merits speci c management.

show abstract

“…Locoregional therapy for BC oligometastases accords with international guidelines ( 36 , 51 ) and has in recent years been reappraised in a Dutch metanalysis that proposed including, among the indications for a multidisciplinary approach, a single metastatic site ( 52 ). Others document long-term survivals and a possibility of a cure in numerous patients with a single metastatic site from BC treated with locoregional therapy (radiotherapy or surgery) associated with systemic therapy especially those with a low tumor burden ( 53 ).…”

Section: Discussionmentioning

confidence: 99%

Selected Patients With Peritoneal Metastases From Breast Cancer May Benefit From Cytoreductive Surgery: The Results of a Multicenter Survey

et al. 2022

View full text Add to dashboard Cite

BackgroundEven though breast cancer is the most frequent extra-abdominal tumor causing peritoneal metastases, clear clinical guidelines are lacking. Our aim is to establish whether cytoreductive surgery (CRS) could be considered in selected patients with peritoneal metastases from breast cancer (PMBC) to manage abdominal spread and allow patients to resume or complete other medical treatments.MethodsWe considered patients with PMBC treated in 10 referral centers from January 2002 to May 2019. Clinical data included primary cancer characteristics (age, histology, and TNM) and data on metastatic disease (interval between primary BC and PM, molecular subtype, other metastases, and peritoneal spread). Overall survival (OS) was estimated using the Kaplan–Meier method. Univariate and multivariable data for OS were analyzed using the Cox proportional hazards model.ResultsOf the 49 women with PMBC, 20 were treated with curative aim (CRS with or without HIPEC) and 29 were treated with non-curative procedures. The 10-year OS rate was 27%. Patients treated with curative intent had a better OS than patients treated with non-curative procedures (89.2% vs. 6% at 36 months, p < 0.001). Risk factors significantly influencing survival were age at primary BC, interval between BC and PM diagnosis, extra-peritoneal metastases, and molecular subtype.ConclusionsThe improved outcome in selected cases after a multidisciplinary approach including surgery should lead researchers to regard PMBC patients with greater attention despite their scarce epidemiological impact. Our collective efforts give new information, suggest room for improvement, and point to further research for a hitherto poorly studied aspect of metastatic BC.

show abstract

Long-term outcomes of oligometastatic breast cancer patients treated with curative intent: an updated report

Cited by 11 publications

References 21 publications

Oligometastatic breast cancer: Dissecting the clinical and biological uniqueness of this emerging entity. Can we pursue curability?

Oligometastatic breast cancer: Dissecting the clinical and biological uniqueness of this emerging entity. Can we pursue curability?

Clinical and pathological characterization of 158 consecutive and unselected oligometastatic breast cancers in a single institution

Selected Patients With Peritoneal Metastases From Breast Cancer May Benefit From Cytoreductive Surgery: The Results of a Multicenter Survey

Contact Info

Product

Resources

About